Table 1.
Baseline demographics
| Variable (N = 8 patients) | Median (IQR) |
|---|---|
| Age, years | 58.5 (50.8–62.3) |
| Male, % | 5 (63) |
| Height, cm | 171.35 (160.6–175.93) |
| Weight, kg | 83.05 (73–88.13) |
| BMI, kg/m2 | 29.4 (25.3–32.4) |
| BSA, m2 | 1.83 (1.6–2.2) |
| BUN, mg/dL | 31 (21–37.5) |
| Scr, mg/dL | 1.64 (1.14–2.89) |
| CrCL, mL/min | 39 (29.5–62.5) |
| ECMO flow rates, mL/min | |
| T = 6 | 3980 (3493.75–4132.5) |
| T = 12 | 3867.5 (3457.5–4078.75) |
| T = 18 | 3867.5 (3513.75–4078.75) |
| T = 24 | 3795.5 (3451.25–4063.75) |
| Vancomycin concentrations, mcg/mL | |
| Pre-oxygenator, 6-h post-dose | 24.9 (10–34.95) |
| Post-oxygenator, 6-h post-dose | 26.05 (9.825–33.55) |
| Pre-oxygenator, 12-h post-dose | 15.95 (6.575–26.5) |
| Post-oxygenator, 12-h post-dose | 15.45 (6.3–22.325) |
| Pre-oxygenator, 18-h post-dose | 18.5 (12.65–23.6) |
| Post-oxygenator, 18-h post-dose | 17.6 (12.125–23.95) |
| Pre-oxygenator, 24-h post-dose | 13.1 (8.875–17.375) |
| Post-oxygenator, 24-h post-dose | 12.7 (8.9–17.175) |
| Indication, count (%) | |
| Empiric treatment of infection | 7 (87) |
| Definitive treatment of infection | 1 (13) |
| Infectious site, presumed or confirmed, n (%) | |
| Pulmonary system | 4 (50) |
| Vascular | 6 (75) |
| Intraabdominal | 1 (12.5) |
BMI body mass index, BSA body surface area, BUN blood urea nitrogen, CrCL creatinine clearance, ECMO extracorporeal membrane oxygenation, IQR interquartile range, Scr serum creatinine